ML089 is a potent, selective, and orally available phosphomannose isomerase (PMI) inhibitor with an IC50 of 1.3 µM. ML089 can be used for the research of congenital disorder of glycosylation Ia[1][2].
[1]. Russell Dahl, et al. Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J Med Chem. 2011 May 26;54(10):3661-8.
















